China Lodging Group Enters Into Definitive Agreement to Acquire Crystal Orange Hotels
Feb 27, 2017 12:01 pm UTC| Business
SHANGHAI, China, Feb. 27, 2017 -- China Lodging Group, Limited (NASDAQ:HTHT) (“China Lodging” or the “Company”), a leading hotel chain operator in China, today announced that its wholly-owned subsidiary China Lodging...
Feb 27, 2017 12:01 pm UTC| Business
-- Fourth-Quarter 2016 Net Sales of $310.3 Million; Up 27 Percent ---- Fourth-Quarter 2016 Net Loss of $130.5 Million(1); Adjusted EBITDA of $136.4 Million -- -- Fourth-Quarter 2016 Operating Cash Flow of $139.2...
Feb 27, 2017 12:01 pm UTC| Business
-- Fourth-Quarter 2016 Net Sales of $310.3 Million; Up 27 Percent ---- Fourth-Quarter 2016 Net Loss of $130.5 Million(1); Adjusted EBITDA of $136.4 Million -- -- Fourth-Quarter 2016 Operating Cash Flow of $139.2...
On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
Feb 27, 2017 12:01 pm UTC| Business
LEIDEN, the Netherlands, Feb. 27, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare...
On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
Feb 27, 2017 12:01 pm UTC| Business
LEIDEN, the Netherlands, Feb. 27, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare...
Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Feb 27, 2017 12:01 pm UTC| Business
WALTHAM, Mass., Feb. 27, 2017 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its...
Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Feb 27, 2017 12:01 pm UTC| Business
WALTHAM, Mass., Feb. 27, 2017 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its...